Abstract
Following recent regional court decisions on the infringement of second medical use patent claims, the German concept of manifest arrangement—previously believed to provide a safe harbor for generic pharmaceutical companies as long as they skinny-labeled their products—may be subject to a new interpretation. The German decisions are part of a Europe wide series of decisions on the same or similar subject matter and prove to be patent owner friendly.
First Page
245
Recommended Citation
Matthias Zigann,
Infringement of Swiss-Type Second Medical Use Patent Claims in Germany—Recent Developments in Case Law,
12 Wash. J. L. Tech. & Arts
245
(2017).
Available at:
https://digitalcommons.law.uw.edu/wjlta/vol12/iss3/4
Included in
Comparative and Foreign Law Commons, Food and Drug Law Commons, Intellectual Property Law Commons